GlassScriptPhysician profile
Sara M Breeden
NPI 1093700056
$7,040.32
in general payments reported to CMS, 2019-2025
49 companies · $1,761 in 2025
The $1,761 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $822 · 2020: $282 · 2021: $565 · 2022: $678 · 2023: $1,290 · 2024: $1,642 · 2025: $1,761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,685 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,684.59 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,107.38 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,081.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $917.26 | 2019-2025 | |
| Abbvie INC. | $603.88 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $584.69 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $254.00 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Merck Sharp & Dohme LLC | $202.32 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $192.80 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.62 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $179.88 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $130.19 | 2022-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $113.23 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $106.06 | 2021-2025 | |
| Astellas Pharma US INC | $105.37 | 2019-2024 | Myrbetriq, Veozah |
| Actelion Pharmaceuticals US, INC. | $105.12 | 2022-2025 | Uptravi, Opsumit |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Breeden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.